Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Cary Street Partners Financial LLC

Key Points

• Cary Street Partners Financial LLC reduced its holdings in Regeneron Pharmaceuticals by 79%, ending the first quarter with just 255 shares, valued at approximately $162,000.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Regeneron Pharmaceuticals, with a projected price target of $841.30.
• The company reported an EPS of $12.89 for the latest quarter, significantly exceeding analysts' expectations of $8.43, alongside revenue of approximately $3.68 billion.

Cary Street Partners Financial LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 79.0% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 255 shares of the biopharmaceutical company's stock after selling 959 shares during the period. Cary Street Partners Financial LLC's holdings in Regeneron Pharmaceuticals were worth $162,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $32,000. Curat Global LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $32,000. Finally, American National Bank & Trust purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $44,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on REGN. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $835.74.

Regeneron Pharmaceuticals Trading Up 0.9%

Shares of REGN stock traded up $5.00 during mid-day trading on Wednesday, reaching $561.55. The company's stock had a trading volume of 1,095,985 shares, compared to its average volume of 1,113,843. The company's 50 day simple moving average is $539.27 and its 200-day simple moving average is $597.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $59.52 billion, a PE ratio of 14.15, a price-to-earnings-growth ratio of 1.85 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm posted $11.56 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.